Literature DB >> 20304810

Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells.

Haiyan Li1, Sungyoul Hong, Jianfei Qian, Yuhuan Zheng, Jing Yang, Qing Yi.   

Abstract

The bone and immune systems are closely related through cellular and molecular interactions. Because bone-resorbing osteoclasts (OCs) are derived from the monocyte/macrophage lineage, similar to dendritic cells (DCs), we hypothesized that OCs could serve as antigen-presenting cells (APCs) to activate T cells. In this study, OCs were generated from human monocytes with stimulation by receptor activator of nuclear factor kappaB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF). Results showed that, similar to DCs, OCs express major histocompatibility complex (MHC) classes I and II, and CD80, CD86, and CD40; and uptake soluble antigens. OCs secrete interleukin-10 (IL-10), transforming growth factor-beta (TGF-beta), IL-6, and tumor necrosis factor-alpha (TNF-alpha), but not IL-12p70. OCs present allogeneic antigens and activate both CD4+ and CD8+ alloreactive T cells in an MHC-restricted fashion. OCs also present soluble protein tetanus toxoid to activate autologous CD4+ T cells. These findings indicate that OCs can function as APCs and activate both CD4+ and CD8+ T cells. Thus, our study provides new insight into the effect of OCs on the immune system and may help develop novel strategies for treating diseases such as rheumatoid arthritis and multiple myeloma, which affect both the bone and immune systems.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20304810      PMCID: PMC2910608          DOI: 10.1182/blood-2009-11-255026

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

Review 1.  Immunobiology of dendritic cells.

Authors:  J Banchereau; F Briere; C Caux; J Davoust; S Lebecque; Y J Liu; B Pulendran; K Palucka
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Bone versus immune system.

Authors:  J R Arron; Y Choi
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

Review 3.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

4.  The inhibitory effect of interleukin-10 on mouse osteoclast formation involves novel tyrosine-phosphorylated proteins.

Authors:  M H Hong; H Williams; C H Jin; J W Pike
Journal:  J Bone Miner Res       Date:  2000-05       Impact factor: 6.741

5.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.

Authors:  Y Y Kong; U Feige; I Sarosi; B Bolon; A Tafuri; S Morony; C Capparelli; J Li; R Elliott; S McCabe; T Wong; G Campagnuolo; E Moran; E R Bogoch; G Van; L T Nguyen; P S Ohashi; D L Lacey; E Fish; W J Boyle; J M Penninger
Journal:  Nature       Date:  1999-11-18       Impact factor: 49.962

6.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.

Authors:  H Takayanagi; K Ogasawara; S Hida; T Chiba; S Murata; K Sato; A Takaoka; T Yokochi; H Oda; K Tanaka; K Nakamura; T Taniguchi
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

7.  Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor kappaB ligand (RANKL).

Authors:  G C Nicholson; M Malakellis; F M Collier; P U Cameron; W R Holloway; T J Gough; C Gregorio-King; M A Kirkland; D E Myers
Journal:  Clin Sci (Lond)       Date:  2000-08       Impact factor: 6.124

Review 8.  Bone resorption by osteoclasts.

Authors:  S L Teitelbaum
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

Review 9.  Regulatory mechanisms of osteoblast and osteoclast differentiation.

Authors:  T Katagiri; N Takahashi
Journal:  Oral Dis       Date:  2002-05       Impact factor: 3.511

Review 10.  Harnessing human dendritic cell subsets to design novel vaccines.

Authors:  Jacques Banchereau; Eynav Klechevsky; Nathalie Schmitt; Rimpei Morita; Karolina Palucka; Hideki Ueno
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

View more
  82 in total

1.  Chemotactic and immunoregulatory properties of bone cells are modulated by endotoxin-stimulated lymphocytes.

Authors:  Hrvoje Cvija; Natasa Kovacic; Vedran Katavic; Sanja Ivcevic; Hector Leonardo Aguila; Ana Marusic; Danka Grcevic
Journal:  Inflammation       Date:  2012-10       Impact factor: 4.092

2.  Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection.

Authors:  Dallas Jones; Laurie H Glimcher; Antonios O Aliprantis
Journal:  J Clin Invest       Date:  2011-07-01       Impact factor: 14.808

Review 3.  The roles of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcification.

Authors:  Linda Demer; Yin Tintut
Journal:  Circ Res       Date:  2011-06-10       Impact factor: 17.367

Review 4.  New developments in osteoimmunology.

Authors:  Hiroshi Takayanagi
Journal:  Nat Rev Rheumatol       Date:  2012-10-16       Impact factor: 20.543

Review 5.  Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts.

Authors:  Brendan F Boyce
Journal:  J Bone Miner Res       Date:  2013-04       Impact factor: 6.741

Review 6.  Vitamin D in rheumatoid arthritis-towards clinical application.

Authors:  Louisa E Jeffery; Karim Raza; Martin Hewison
Journal:  Nat Rev Rheumatol       Date:  2015-10-13       Impact factor: 20.543

7.  Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.

Authors:  Gang An; Chirag Acharya; Xiaoyan Feng; Kenneth Wen; Mike Zhong; Li Zhang; Nikhil C Munshi; Lugui Qiu; Yu-Tzu Tai; Kenneth C Anderson
Journal:  Blood       Date:  2016-07-14       Impact factor: 22.113

Review 8.  Inflammatory diseases and bone fragility.

Authors:  K Briot; P Geusens; I Em Bultink; W F Lems; C Roux
Journal:  Osteoporos Int       Date:  2017-09-15       Impact factor: 4.507

9.  Pulsed low-dose RANKL as a potential therapeutic for postmenopausal osteoporosis.

Authors:  Anna Cline-Smith; Jesse Gibbs; Elena Shashkova; Zachary S Buchwald; Deborah V Novack; Rajeev Aurora
Journal:  JCI Insight       Date:  2016-08-18

10.  T cells from chronic bone infection show reduced proliferation and a high proportion of CD28⁻ CD4 T cells.

Authors:  G Kumar; P-M Roger; M Ticchioni; C Trojani; R Bernard de Dompsur; N Bronsard; M Carles; E Bernard
Journal:  Clin Exp Immunol       Date:  2014-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.